TY - JOUR
T1 - Lymphocyte migration and multiple sclerosis
T2 - Relation with disease course and therapy
AU - Prat, Alexandre
AU - Al-Asmi, Abdulla
AU - Duquette, Pierre
AU - Antel, Jack P.
PY - 1999
Y1 - 1999
N2 - Lymphocyte migration into the central nervous system is a central event in lesion formation in multiple sclerosis. By using a fibronectin-coated membrane Boyden chamber assay, we observed that migration rates of immediately ex vivo lymphocytes from patients with relapsing-remitting, with or without concurrent clinical relapse, or with secondary progressive disease, were increased compared with healthy donors. Migration rates of lymphocytes from relapsing-remitting multiple sclerosis patients receiving either glatiramer acetate (Copaxone 20 mg daily) or interferon-β1b (Betaseron 8 MIU, three times per week) were significantly reduced compared with untreated relapsing-remitting patients. In vitro treatment with interferon-β1b (1,000 U/ml), but not glatiramer acetate (20 μg/ml), significantly reduced lymphocyte-migration rates, suggesting that the effects of these two therapeutic agents on migration result from different mechanisms of actions. Interferon-β1b acts, at least in part, by a direct effect on this cell property, whereas glatiramer acetate effects are indirect.
AB - Lymphocyte migration into the central nervous system is a central event in lesion formation in multiple sclerosis. By using a fibronectin-coated membrane Boyden chamber assay, we observed that migration rates of immediately ex vivo lymphocytes from patients with relapsing-remitting, with or without concurrent clinical relapse, or with secondary progressive disease, were increased compared with healthy donors. Migration rates of lymphocytes from relapsing-remitting multiple sclerosis patients receiving either glatiramer acetate (Copaxone 20 mg daily) or interferon-β1b (Betaseron 8 MIU, three times per week) were significantly reduced compared with untreated relapsing-remitting patients. In vitro treatment with interferon-β1b (1,000 U/ml), but not glatiramer acetate (20 μg/ml), significantly reduced lymphocyte-migration rates, suggesting that the effects of these two therapeutic agents on migration result from different mechanisms of actions. Interferon-β1b acts, at least in part, by a direct effect on this cell property, whereas glatiramer acetate effects are indirect.
UR - http://www.scopus.com/inward/record.url?scp=0032838096&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0032838096&partnerID=8YFLogxK
U2 - 10.1002/1531-8249(199908)46:2<253::AID-ANA16>3.0.CO;2-C
DO - 10.1002/1531-8249(199908)46:2<253::AID-ANA16>3.0.CO;2-C
M3 - Article
C2 - 10443892
AN - SCOPUS:0032838096
SN - 0364-5134
VL - 46
SP - 253
EP - 256
JO - Annals of Neurology
JF - Annals of Neurology
IS - 2
ER -